Process for preparation of rosuvastatin calcium
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsValerie Niddam-Hildesheim, Greta Sterimbaum
Life of this patent
Estimating the term…
Abstract
The present invention provides processes for preparing calcium salts of statin, particularly rosuvastatin calcium salt substantially free of impurities on an industrial scale.
Claims38
A process for producing rosuvastatin calcium comprising:
- a) reacting a C1 to C4 alkyl ester of rosuvastatin with a base in presence of a C1 to C4 alcohol to obtain a solution;
- b) concentrating the solution to obtain a residue;
- c) combining the residue with water to obtain an aqueous solution;
- d) washing the aqueous solution with a water immiscible organic solvent;
- e) removing traces of the organic solvent;
- f) adding a source of calcium to the solution to precipitate rosuvastatin calcium;
- and
- g) recovering the rosuvastatin calcium salt.
A process for producing rosuvastatin calcium salt comprising:
- a) combining a suspension of t-butyl ester of rosuvastatin in ethanol with sodium hydroxide to obtain a solution, and stirring during or after the combining;
- b) evaporating the solution under reduced pressure to obtain a residue;
- c) combining the residue with water to obtain an aqueous solution;
- d) washing the aqueous solution with ethyl acetate;
- e) evaporating traces of the ethyl acetate under reduced pressure;
- f) adding calcium chloride to the solution to precipitate rosuvastatin calcium;
- and
- g) filtering the rosuvastatin calcium salt.
A process for producing rosuvastatin calcium salt comprising:
- a) reacting a C1 to C4 alkyl ester of rosuvastatin in a water immiscible phase, with a base in an aqueous phase, in presence of a phase transfer catalyst to obtain rosuvastatin in the aqueous phase;
- b) adding a source of calcium to the aqueous phase to precipitate rosuvastatin calcium;
- and
- c) recovering the rosuvastatin calcium salt;
- with the proviso that:
- (i) the process further comprising a step of removing traces of the water immiscible solvent before adding a source of calcium;
- wherein the ester is a t-butyl ester:
- (ii) the process further comprises stirring during the reaction;
- (iii) wherein the water immiscible phase is a solvent selected from the group consisting of substituted and unsubstituted C5 to C12 hydrocarbon, C4 to C7 ester, C4 to C7 ketone and mixtures thereof;
- or
- (iv) the hydrocarbon is toluene or chlorobenzene.
A process for producing rosuvastatin calcium salt comprising:
- a) reacting, t-butyl ester of rosuvastatin with sodium hydroxide in presence of water, a tetrabutylammonium phase transfer catalyst and an organic solvent selected from the group consisting of toluene and chlorobenzene to obtain rosuvastatin in the water;
- b) removing traces of the toluene or chlorobenzene from the water;
- c) adding calcium chloride to the water to precipitate rosuvastatin calcium;
- and
- d) filtering the rosuvastatin calcium salt.
A process for producing rosuvastatin calcium salt substantially free of impurities comprising the steps of:
- a) reacting a C1 to C4 ester of rosuvastatin with a base in a two phase system of water and acetonitrile;
- b) concentrating the water phase to obtain a residue;
- c) adding a source of calcium and water to the residue to form a solution in water;
- and
- d) recovering rosuvastatin calcium as a precipitate.
A process for producing rosuvastatin calcium comprising:
- a) preparing a solution of rosuvastatin sodium;
- b) concentrating the solution to obtain a residue;
- c) combining the residue with water to obtain an aqueous solution;
- d) washing the aqueous solution with a water immiscible organic solvent;
- e) removing traces of the organic solvent;
- f) adding a source of calcium to the solution to precipitate rosuvastatin calcium;
- and
- g) recovering the rosuvastatin calcium salt.
Rosuvastatin calcium in solid state having less than or of about 0.4% total impurities as measured by area percentage HPLC.
Rosuvastatin calcium in solid state, wherein the calcium salt does not have detectable level of impurities when measured by HPLC at RRT 1.26.
Dependencies are inferred from the claim text.